Clinical Trials Logo

Dementia Frontal clinical trials

View clinical trials related to Dementia Frontal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05023564 Recruiting - Dementia Clinical Trials

PUMCH Dementia Longitudinal Cohort Study

Start date: December 1, 2020
Phase:
Study type: Observational

The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.

NCT ID: NCT04924361 Recruiting - Dementia Clinical Trials

Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

Start date: December 1, 2020
Phase:
Study type: Observational

Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.

NCT ID: NCT03672448 Recruiting - Depression Clinical Trials

The China Longitudinal Aging Study of Cognitive Impairment

Start date: September 1, 2018
Phase:
Study type: Observational

Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. Based on the above understanding, the study carry out the population cohort study based on accurate diagnosis and construct the high standard information and sample bank. The study will establish the standard and quality system of geriatric cognitive disorders cohort study (unified standards and norms). The study will integrate the standard biological samples stratified acquisition function module (homogeneity and precision) of elderly cognitive disorders, and complete the construction of biological samples bank and clinical diagnosis and treatment information database. The study will apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study will evaluate whether peripheral nerve degeneration can predict central nervous system degeneration based on the large cohort of elderly study. In addition, The study will make an effective supplement the sample bank construction of Shanghai Mental Health Center.

NCT ID: NCT03672266 Recruiting - Alzheimer Disease Clinical Trials

Studies of Brain and Body Interaction

Start date: August 1, 2018
Phase:
Study type: Observational

The goal of this study is to characterize biophysiolgoical signals as a comprehensive profile of the nervous systems in order to understand interactions between the brain and body, while an individual performs naturalistic behaviors (ex. walking, pointing) and while breathing at a slow controlled pace. The investigators aim to study these interactions among a variety of populations, from healthy individuals to those with disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD (Attention-deficit/hyperactivity disorder) diagnosis, Asperger's Syndrome, Alzheimer's Disease, and/or Fragile X syndrome

NCT ID: NCT03644043 Recruiting - Alzheimer Disease Clinical Trials

Evidence Amyloid Scan EEG Study

EASES
Start date: July 20, 2018
Phase:
Study type: Observational [Patient Registry]

The Evidence Amyloid Study EEG (EASE) establishes an open-label, longitudinal cohort study to measure of neurological functioning during the onset and progression of cognitive decline in preclinical Alzheimer's patients using quantitative electroencephalography (qEEG) measures (P300, P50, and reaction time). Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi headset with the WAVi EEG P300/P50 system, along with the structured clinical interviews and assessments for baseline screening or mild cognitive impairment which are standard of care.